AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22011515 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-HLM
Number of subjects: 76
Study 22011515 — intervention group
Group type: COMPARATOR
Intervention: OPCAB
Number of subjects: 76
Study 18280971 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide [Ca(OH)2]
Number of subjects: 0
Study 18280971 — intervention group
Group type: COMPARATOR
Intervention: Single Bond adhesive system (SBAS)
Number of subjects: 0
Study 17146025 — intervention group
Group type: COMPARATOR
Intervention: Health plan-based lifestyle intervention (bimonthly group meetings, quarterly coaching telephone calls, and weekly self-monitoring)
Number of subjects: 0
Study 17146025 — intervention group
Group type: COMPARATOR
Intervention: Health plan-based lifestyle intervention
Number of subjects: 0
Study 17146025 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12750437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valacyclovir administration
Number of subjects: 0
Study 12750437 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir administration
Number of subjects: 0
Study 12750437 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10773130 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin 910 suture
Number of subjects: 340
Study 10773130 — intervention group
Group type: COMPARATOR
Intervention: Polydioxanone loop suture
Number of subjects: 340
Study 10773130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sutures
Number of subjects: 340
Study 8813775 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak TNF-alpha secretion in patients with systemic complications
Number of subjects: 26
Study 8813775 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak IL-6 secretion in patients with systemic complications
Number of subjects: 26
Study 8813775 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak IL-8 secretion in patients with systemic complications
Number of subjects: 26
Study 8813775 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak IL-1 beta secretion
Number of subjects: 26
Study 1349450 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1-blockade)
Number of subjects: 9
Study 1349450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3909500 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 300 mg daily for 2 weeks
Number of subjects: 0
Study 3909500 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 600 mg daily for 2 weeks
Number of subjects: 0
Study 3909500 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherogenic diet with 100 mg vitamin E daily
Number of subjects: 0
Study 3909500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31852697 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Health Choices podcast
Number of subjects: 84
Study 29365382 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoids combined with inhaled steroid (Budesonide suspension 1.0 mg for inhalation, oxygen-driven atomizing inhalation, every 30 minutes, 2 times in a row, then every 12 hours)
Number of subjects: 78
Study 29365382 — intervention group
Group type: COMPARATOR
Intervention: Systemic glucocorticoids (Dexamethasone injection 0.3‐0.5 mg/kg for 1‐3 days)
Number of subjects: 78
Study 26662710 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic Ketogenic Diet (KD)
Number of subjects: 104
Study 26662710 — intervention group
Group type: COMPARATOR
Intervention: Modified Atkins Diet (MAD)
Number of subjects: 104
Study 25359002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tornado program (accelerated-track diagnosis and treatment planning, psychoeducation, pharmacological treatment by primary care physicians)
Number of subjects: 90
Study 25359002 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 90
Study 22616062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic material titanium niobium oxynitride ([Ti,Nb]ON) with plasma‐chemical oxidation treatment
Number of subjects: 6
Study 22616062 — intervention group
Group type: COMPARATOR
Intervention: Metal surfaces (titanium-tantalum alloy and tantalum)
Number of subjects: 6
Study 20736206 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping bare metal stents (BMS)
Number of subjects: 71
Study 20736206 — intervention group
Group type: EXPERIMENTAL
Intervention: Overlapping drug-eluting stents (DES)
Number of subjects: 71
Study 18359501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking four objects
Number of subjects: 0
Study 18359501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking multiple objects
Number of subjects: 0
Study 15610953 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate plus risperidone (TPMG)
Number of subjects: 74
Study 15610953 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex plus risperidone (DVPG)
Number of subjects: 74
Study 11986913 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular nimodipine 30 mg every 6 h
Number of subjects: 19
Study 11986913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine AP 120 mg every 24 h
Number of subjects: 19
Study 10440432 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 258
Study 10440432 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 258
Study 7486485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (eicosapentaenoic and docosahexaenoic acids), 4 g/d
Number of subjects: 78
Study 7486485 — intervention group
Group type: COMPARATOR
Intervention: Corn oil placebo, 4 g/d
Number of subjects: 78
Study 12283375 — intervention group
Group type: EXPERIMENTAL
Intervention: Filshie Mark VI clips
Number of subjects: 289
Study 12283375 — intervention group
Group type: COMPARATOR
Intervention: Hulka-Clemens clips
Number of subjects: 289
Study 12283375 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 289
Study 453056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen intake of about 280 mg N/kg per day (mixed animal and plant protein sources) for 8 weeks
Number of subjects: 21
Study 453056 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen intake of about 90 mg N/kg per day (egg protein) for 11 weeks
Number of subjects: 21
Study 31605197 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g inulin plus 10 g resistant maltodextrin
Number of subjects: 116
Study 31605197 — intervention group
Group type: COMPARATOR
Intervention: 20 g placebo supplementation
Number of subjects: 116
Study 31290566 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib with no/nonsignificant gastrectomy
Number of subjects: 133
Study 31290566 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib with major gastrectomy
Number of subjects: 133
Study 31290566 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib pharmacokinetics in major gastrectomy
Number of subjects: 133
Study 31290566 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib pharmacokinetics in no/nonsignificant gastrectomy
Number of subjects: 133
Study 27508295 — intervention group
Group type: COMPARATOR
Intervention: Serum IGF-1 levels in SGA infants (27.6 ± 17.7 ng/ml)
Number of subjects: 40
Study 27508295 — intervention group
Group type: COMPARATOR
Intervention: Aortic strain in SGA infants (10.2 ± 3.1%)
Number of subjects: 40
Study 27508295 — intervention group
Group type: COMPARATOR
Intervention: Aortic distensibility in SGA infants (0.73 ± 0.19 cm2/dyn × 10‐4)
Number of subjects: 40
Study 27508295 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure in SGA infants
Number of subjects: 40
Study 27508295 — intervention group
Group type: COMPARATOR
Intervention: Aortic intima-media thickness (aIMT) in relation to body weight in SGA infants (383 ± 163 μm/kg)
Number of subjects: 40
Study 27508295 — intervention group
Group type: COMPARATOR
Intervention: Aortic stiffness index in relation to body weight in SGA infants (2.0 ± 1.7)
Number of subjects: 40
Study 27508295 — intervention group
Group type: COMPARATOR
Intervention: Arterial pressure-strain elastic modulus in SGA infants (293 ± 72 mm Hg)
Number of subjects: 40
Study 25172025 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 73
Study 25172025 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 73
Study 25172025 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (tDCS and sertraline)
Number of subjects: 73
Study 25172025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham control)
Number of subjects: 73
Study 24136883 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without bevacizumab
Number of subjects: 663
Study 24136883 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with bevacizumab
Number of subjects: 663
Study 22145775 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse containing Enteromorpha linza extract
Number of subjects: 55
Study 22145775 — intervention group
Group type: COMPARATOR
Intervention: Listerine (positive control)
Number of subjects: 55
Study 18951992 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin-B (L‐AmB)
Number of subjects: 271
Study 18951992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 16082155 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin I(2) (PGI(2)), norepinephrine and dopamine (PGI(2) group)
Number of subjects: 68
Study 16082155 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin, norepinephrine and dopamine (control group)
Number of subjects: 68
Study 12383322 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 236
Study 12383322 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 236
Study 10089262 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise during hemodialysis (3 times a week, gradually increasing to 45 minutes at 60% to 80% maximal heart rate)
Number of subjects: 11
Study 10089262 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise during hemodialysis
Number of subjects: 11
Study 10089262 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (non-exercising)
Number of subjects: 11
Study 7591755 — intervention group
Group type: EXPERIMENTAL
Intervention: Full hospital cost accounting model for surgery and anesthesia
Number of subjects: 0
Study 7591755 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective multicenter economic clinical trial
Number of subjects: 0
Study 2262461 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) 250 mg oral doses
Number of subjects: 7
Study 2262461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 434096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose gradient purified vaccine
Number of subjects: 310
Study 434096 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetron purified vaccine
Number of subjects: 310
Study 434096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 30953522 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-week ketogenic diet (KD)
Number of subjects: 22
Study 28371230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving family caregivers (FC) with seven planned encounters over 3 days, each including a 30-min visit at the patient's bedside.
Number of subjects: 30
Study 28371230 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 30
Study 26081597 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptamine 3 (5-HT3) antagonist + corticosteroid as antiemetic treatment
Number of subjects: 240
Study 23404064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (dopamine receptor agonist)
Number of subjects: 22
Study 23404064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21367927 — intervention group
Group type: EXPERIMENTAL
Intervention: TPD 20 μg daily
Number of subjects: 55
Study 21367927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 20396750 — intervention group
Group type: EXPERIMENTAL
Intervention: Afobazole (30-60 mg/day for 1 month)
Number of subjects: 0
Study 20396750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16934392 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-based screening (biennial testing)
Number of subjects: 20000
Study 16934392 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PSA screening)
Number of subjects: 20000
Study 15592551 — intervention group
Group type: COMPARATOR
Intervention: Audit and Feedback (A and F)
Number of subjects: 63
Study 15592551 — intervention group
Group type: COMPARATOR
Intervention: Computer Aided Learning (CAL)
Number of subjects: 63
Study 15592551 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline and Postgraduate Education Course (PGEC)
Number of subjects: 63
Study 15592551 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and Feedback (A and F) and Computer Aided Learning (CAL)
Number of subjects: 63
Study 11331253 — intervention group
Group type: EXPERIMENTAL
Intervention: phVEGF‐2 (200 microgram total dose, 6 injections of 6.0 mL)
Number of subjects: 6
Study 11331253 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mock procedure)
Number of subjects: 6
Study 9927915 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive program for mothers and children starting during pregnancy
Number of subjects: 86
Study 9927915 — intervention group
Group type: COMPARATOR
Intervention: Control group (children from various kindergartens)
Number of subjects: 86
Study 7993958 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.5 mg/kg orally)
Number of subjects: 23
Study 7993958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3053312 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacid regimen (1 tablet q.i.d.; acid-neutralizing capacity, 120 mmol/day)
Number of subjects: 150
Study 3053312 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (800 mg nocte)
Number of subjects: 150
Study 3053312 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacid regimen
Number of subjects: 150
Study 30373502 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility Feedback Device (MFD) used weekly for 6 months
Number of subjects: 86
Study 30373502 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 86
Study 30373502 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 86
Study 29267990 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral electroconvulsive therapy
Number of subjects: 73
Study 29267990 — intervention group
Group type: COMPARATOR
Intervention: Algorithm-based pharmacologic treatment
Number of subjects: 73
Study 28566029 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainers' competence in delivery of the program
Number of subjects: 764
Study 28566029 — intervention group
Group type: COMPARATOR
Intervention: Trainers' adherence to program content
Number of subjects: 764
Study 26432772 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella supplement (4 tablets, total chlorophyll ≈8.3 mg/tablet, three times a day for 2 weeks)
Number of subjects: 12
Study 26432772 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorella supplement
Number of subjects: 12
Study 26432772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24448936 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (400 mg)
Number of subjects: 1193
Study 21399681 — intervention group
Group type: COMPARATOR
Intervention: Genital herpes suppression intervention
Number of subjects: 151
Study 21399681 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline viral load
Number of subjects: 151
Study 21399681 — intervention group
Group type: EXPERIMENTAL
Intervention: Time on study
Number of subjects: 151
Study 19034737 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone at 150 mg/day
Number of subjects: 0
Study 15161060 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin + leukofiltration
Number of subjects: 90
Study 15161060 — intervention group
Group type: COMPARATOR
Intervention: aprotinin alone
Number of subjects: 90
Study 11207640 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH) at 3 IU/(m(2) body surface.day)
Number of subjects: 78
Study 11207640 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH) at 6 IU/(m(2) body surface.day)
Number of subjects: 78
Study 11207640 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH)
Number of subjects: 78
Study 9628422 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching to grasp a target in the presence of an obstacle (nontarget object)
Number of subjects: 0
Study 9628422 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacle interpretation of nontarget objects
Number of subjects: 0
Study 7989081 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg once daily, adjusted to 10 mg once daily if necessary after 2 weeks
Number of subjects: 20
Study 2460421 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programs presented at three critical points: Pretreatment, Treatment Week 2, and Final Treatment Week.
Number of subjects: 72
Study 2460421 — intervention group
Group type: COMPARATOR
Intervention: Patient education programs with pretest and posttest assessments.
Number of subjects: 72
Study 2460421 — intervention group
Group type: COMPARATOR
Intervention: Final Treatment Week program with pretest.
Number of subjects: 72
Study 2460421 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programs overall.
Number of subjects: 72
Study 29724194 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive package of interventions for maternal and neonatal health promotion
Number of subjects: 30
Study 29724194 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison clusters)
Number of subjects: 30
Study 27380862 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glycolic acid peel
Number of subjects: 90
Study 27380862 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% lactic acid peel
Number of subjects: 90
Study 27380862 — intervention group
Group type: EXPERIMENTAL
Intervention: topical 20% vitamin C
Number of subjects: 90
Study 24821582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50mg (4 weeks on, 2 weeks off)
Number of subjects: 86
Study 24821582 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 86
Study 22532941 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE One with Tetric Evo Ceram and flowable composite (group TF)
Number of subjects: 50
Study 22532941 — intervention group
Group type: COMPARATOR
Intervention: AdheSE One with Tetric Evo Ceram without flowable composite (group T)
Number of subjects: 50
Study 21303745 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg every 8 hours
Number of subjects: 1171
Study 21303745 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 250 mg every 24 hours
Number of subjects: 1171
Study 21303745 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem in levofloxacin-resistant E. coli infections
Number of subjects: 1171
Study 19023827 — intervention group
Group type: EXPERIMENTAL
Intervention: Test cigarettes with activated carbon filters (comparable tar levels)
Number of subjects: 160
Study 19023827 — intervention group
Group type: COMPARATOR
Intervention: Conventional cigarettes (6-mg or 11-mg FTC tar product)
Number of subjects: 160
Study 19023827 — intervention group
Group type: COMPARATOR
Intervention: Stop smoking
Number of subjects: 160
Study 19023827 — intervention group
Group type: EXPERIMENTAL
Intervention: Test cigarettes with activated carbon filters
Number of subjects: 160
Study 15981488 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpupillary thermotherapy (TTT)
Number of subjects: 72
Study 15981488 — intervention group
Group type: COMPARATOR
Intervention: Control (not treated eye)
Number of subjects: 72
Study 11375812 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 450/0.7‐0.8
Number of subjects: 50
Study 11375812 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.6‐0.66
Number of subjects: 50
Study 11375812 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 70/0.5‐0.55
Number of subjects: 50
Study 11375812 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 50
Study 11375812 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.38‐0.45
Number of subjects: 50
Study 9552785 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline 10 mL at 5 minutes after spinal injection (group A)
Number of subjects: 30
Study 9552785 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline 10 mL at 20 minutes after spinal injection (group B)
Number of subjects: 30
Study 9552785 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 30
Study 9552785 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline 10 mL at 7 minutes after spinal injection (group D)
Number of subjects: 30
Study 9552785 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 10 mL at 7 minutes after spinal injection (group E)
Number of subjects: 30
Study 9552785 — intervention group
Group type: EXPERIMENTAL
Intervention: No epidural injection (group F)
Number of subjects: 30
Study 7844481 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological-processing intervention
Number of subjects: 99
Study 7844481 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 99
Study 3395540 — intervention group
Group type: EXPERIMENTAL
Intervention: Water 100 ml administered 2 hours before operation
Number of subjects: 50
Study 3395540 — intervention group
Group type: COMPARATOR
Intervention: Fasted group (control)
Number of subjects: 50
Study 31553119 — intervention group
Group type: EXPERIMENTAL
Intervention: 45% mandelic acid (MA) peel
Number of subjects: 50
Study 31553119 — intervention group
Group type: COMPARATOR
Intervention: 30% salicylic acid (SA) peel
Number of subjects: 50
Study 30896629 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine suppository
Number of subjects: 250
Study 30896629 — intervention group
Group type: COMPARATOR
Intervention: Control group (no povidone-iodine suppository)
Number of subjects: 250
Study 28177167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.1 mg/kg)
Number of subjects: 116